BMS’s Opdivo and Yervoy colorectal cancer trials show promising results
![](https://drhimanshuyadav.com/wp-content/uploads/2024/01/BMSs-Opdivo-and-Yervoy-colorectal-cancer-trials-show-promising-results-1024x683.jpg)
BMS presented this data supporting the use of immune checkpoint inhibitors (ICIs) in combination in patients with newly diagnosed advanced colorectal cancer subtypes at the ASCO Gastrointestinal Cancer Symposium. Credit: Tada Images / Shutterstock. On January 22, BMS announced encouraging findings from the CheckMate -8HW clinical trial, showing that the combination of Opdivo (nivolumab) and […]
BMS’ Opdivo regimen shows promise in colorectal cancer clinical trials
![](https://drhimanshuyadav.com/wp-content/uploads/2024/01/BMS-Opdivo-regimen-shows-promise-in-colorectal-cancer-clinical-trials-1024x576.jpg)
BMS’ Opdivo plus Yervoy significantly improved progression-free survival in patients with MSI-H/dMMR metastatic colorectal cancer. Credit: Bristol-Myers Squibb Company. bristol myers squib (BMS) is a Phase III CheckMate-8HW clinical trial combining Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment option for microsatellite-high instability (MSI-H) or mismatch repair deficiency (dMMR). reported promising data. Metastatic colorectal […]
Bristol-Myers Squibb launches Kibosh into clinical trials for colorectal cancer candidate
![](https://drhimanshuyadav.com/wp-content/uploads/2023/12/Bristol-Myers-Squibb-launches-Kibosh-into-clinical-trials-for-colorectal-cancer.jpeg)
Photo: Bristol-Myers Squibb Building in Munich / iStock Tati Campero Bristol-Myers Squibb is discontinuing a clinical trial studying a combination of Opdivo (nivolumab) and leratorimab, called Opdurag, in patients with stable microsatellite metastatic colorectal cancer. Data from a Phase III trial of the combination, known as Relativity-123, was reviewed by an independent data monitoring board […]